Exhibit 99.1 Ainos Reports First Quarter 2024 Financial Results Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024 US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, May 13, 2024 /Accesswire/ — Ainos, Inc. (NASDAQ: AIMD, AIMDW) (“Ainos”, or the “Company”), a diversified healthcare company focused on the development of novel point-of-care testing (“POCT”), low-dose interferon therapeutics, and synthetic RNA-driven pre ...